Tissium
PrivateLast Round
Debt
Jun 24, 2026
Total Funding Raised
$302.17M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Tissium operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series D Extension round in December 2025.
Tissium is a France-based medtech company that develops a platform of biomorphic programmable polymers for tissue reconstruction.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Advanced Materials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tissium Comparables
Compare Tissium with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regenity Biosciences | 80% | |
| BioCircuit Technologies | 78% | |
| Orthocell Ltd | 77% |
For institutional investors. Book with your work email.
Tissium Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jun 24, 2026 | ||||
| Series D Extension | Dec 31, 2025 | ||||
| Series D Extension | Dec 1, 2025 | ||||
| Series D | May 23, 2023 | ||||
| Series C | Aug 31, 2021 | ||||
Series B | Nov 20, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tissium Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cathay Capital | Series D Extension, Series D |
| BNP Paribas Développement | Series B |
| CapDecisif Management | Series A Extension, Series B, Series A |
| ISALT | Series D |
| European Investment Fund | Series B |
| European Investment Bank Group | Debt |
| Crédit Mutuel Innovation | Series A Extension, Series B, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 47% MoM.
- Mar 18, 2026
Tissium is actively exploring the expansion of its TISSIUM platform into new applications, including nerve repair.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 21, 2026
Tissium prepares the European commercial introduction of ECLIPSIUM, with an initial release expected in 2027.
For institutional investors. Book with your work email.
Tissium Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tissium's valuation, stock price, and market status.
Is Tissium a public or private company?
Tissium is a private company.
What is the current stock price of Tissium?
Tissium is a private company, so its shares have no public market price. Caplight tracks Tissium's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tissium worth (valuation)?
Valuation information for Tissium is not publicly available.
Can I buy Tissium stock?
Tissium shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tissium's last funding round?
Tissium's most recent funding round was Debt on June 24, 2026.
Who are the main investors in Tissium?
Key investors in Tissium include Sofinnova Partners, Omnes Capital, Bpifrance, Crédit Mutuel Equity.
Will Tissium IPO soon?
No public IPO plans have been announced for Tissium.
How can I track Tissium secondary market activity?
Caplight tracks bids, offers, and trades in Tissium's shares on secondary markets.